Waldron Private Wealth LLC reduced its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,755 shares of the biopharmaceutical company’s stock after selling 537 shares during the quarter. Waldron Private Wealth LLC’s holdings in Bristol-Myers Squibb were worth $306,000 as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its holdings in shares of Bristol-Myers Squibb by 0.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,012,753 shares of the biopharmaceutical company’s stock worth $208,561,000 after purchasing an additional 35,653 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Bristol-Myers Squibb by 70.3% in the fourth quarter. Nordea Investment Management AB now owns 1,302,099 shares of the biopharmaceutical company’s stock worth $67,684,000 after purchasing an additional 537,649 shares during the last quarter. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $217,000. Lake Point Wealth Management bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $274,000. Finally, Putnam FL Investment Management Co. grew its holdings in shares of Bristol-Myers Squibb by 17.4% in the fourth quarter. Putnam FL Investment Management Co. now owns 17,784 shares of the biopharmaceutical company’s stock worth $924,000 after purchasing an additional 2,636 shares during the last quarter. Institutional investors and hedge funds own 77.37% of the company’s stock.
Several research analysts have issued reports on the stock. Atlantic Securities upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a report on Wednesday. BMO Capital Markets increased their target price on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. UBS Group dropped their target price on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a report on Thursday, June 13th. Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $53.00 to $55.00 in a report on Friday, May 3rd. Finally, ValuEngine cut shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $55.88.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, beating analysts’ consensus estimates of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The business had revenue of $6.27 billion for the quarter, compared to analysts’ expectations of $6.10 billion. During the same period last year, the business earned $1.01 EPS. The company’s revenue was up 10.0% compared to the same quarter last year. As a group, analysts forecast that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were issued a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.52%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.
In other news, Director Theodore R. Samuels II purchased 5,000 shares of the stock in a transaction dated Thursday, May 16th. The shares were acquired at an average cost of $47.29 per share, for a total transaction of $236,450.00. Following the acquisition, the director now owns 27,000 shares of the company’s stock, valued at $1,276,830. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Robert J. Bertolini purchased 11,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was purchased at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the completion of the acquisition, the director now directly owns 11,397 shares in the company, valued at approximately $509,673.84. The disclosure for this purchase can be found here. 0.13% of the stock is currently owned by company insiders.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: What is the Consumer Price Index (CPI)?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.